S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:CAPR - Capricor Therapeutics Stock Price, Forecast & News

$1.42
+0.08 (+5.97 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$1.36
Now: $1.42
$1.43
50-Day Range
$1.23
MA: $1.54
$1.83
52-Week Range
$1.00
Now: $1.42
$8.85
Volume100,100 shs
Average Volume183,609 shs
Market Capitalization$6.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$1.49 per share

Profitability

Net Income$-15,190,000.00
Net Margins-660.66%

Miscellaneous

EmployeesN/A
Market Cap$6.03 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.


Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.27. The biotechnology company earned $0.14 million during the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 264.61% and a negative net margin of 660.66%. View Capricor Therapeutics' Earnings History.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Capricor Therapeutics.

What price target have analysts set for CAPR?

2 analysts have issued 12 month price targets for Capricor Therapeutics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Capricor Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 533.8% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.

What is the consensus analysts' recommendation for Capricor Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.

Has Capricor Therapeutics been receiving favorable news coverage?

News coverage about CAPR stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Capricor Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Capricor Therapeutics.

Are investors shorting Capricor Therapeutics?

Capricor Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 48,100 shares, an increase of 75.5% from the January 15th total of 27,400 shares. Based on an average daily trading volume, of 154,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.5% of the shares of the stock are sold short. View Capricor Therapeutics' Current Options Chain.

Who are some of Capricor Therapeutics' key competitors?

What other stocks do shareholders of Capricor Therapeutics own?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.97%). View Institutional Ownership Trends for Capricor Therapeutics.

Which institutional investors are buying Capricor Therapeutics stock?

CAPR stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Capricor Therapeutics.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $1.42.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $6.03 million and generates $1.67 million in revenue each year. The biotechnology company earns $-15,190,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis. View Additional Information About Capricor Therapeutics.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is http://www.capricor.com/.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]


MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  666
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel